

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/590,211
Int'l Filing Date	February 23, 2005
First Named Inventor	Jean-Marie BUERSTEDDE
Art Unit	To Be Assigned 1633
Examiner Name	To Be Assigned F. Sajjadi
Attorney Docket Number	P30753US00/21027.002

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-			
	B1	US-			
	C1	US-			
	D1	US-			
	E1	US-			
	F1	US-			
	G1	US-			
	H1	US-			
	I1	US-			
	J1	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/F.S./	K1	WO 00/22111 A1	04-20-2000	Medical Research Council		✓
/F.S./	L1	WO 02/100998 A2	12-19-20002	Medical Research Council		✓
	M1					
	N1					

Examiner
Signature

/Fereydoun Sajjadi/

Date
Considered

01/24/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/590,211
				Int'l Filing Date	February 23, 2005
				First Named Inventor	Jean-Marie BUERSTEDDE
				Art Unit	To Be Assigned 1633
				Examiner Name	To Be Assigned F. Sajjadi
Sheet	2	of	2	Attorney Docket Number	P30753US00/21027.002

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/F.S./	A2	Arakawa <i>et al.</i> , "Immunoglobulin Gene Conversion: Insights from Bursal B Cells and the DT40 Cell Line," <i>Developmental Dynamics</i> , 229:458-464 (2004)	
	B2	Diaz <i>et al.</i> , "Evolution of Somatic Hypermutation and Gene Conversion in Adaptive Immunity," <i>Immunological Reviews</i> , 162:13-24 (1998)	
	C2	Sale <i>et al.</i> , "TdT-Accessible Breaks are Scattered over the Immunoglobulin V Domain in a Constitutively Hypermutating B Cell Line," <i>Immunity</i> , 9:859-869 (1998)	
	D2	Yélamos <i>et al.</i> , "Targeting of non-Ig Sequences in Place of the V Segment by Somatic Hypermutation," <i>Nature</i> , 376:225-229 (1995)	
↓	E2	International Search Report from PCT/EP2005/001897 (mailed Aug. 17, 2005)	
	F2		
	G2		
	H2		
	I2		
	J2		
	K2		
	L2		
	M2		

Examiner Signature	/Fereydoun Sajjadi/	Date Considered	01/24/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

21027.002/P30753US00

APPLICATION NO.

10/590,211

APPLICANTS

Jean-Marie BUERSTEDDE *et al.*

FILING DATE

August 22, 2006

GROUP

1633

~~To Be Assigned~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AAI						
	ABI						
	ACI						
	ADI						
	AEI						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
Duplicate	AFI	WO 00/22111	04/2000	WIPO			Yes No
Duplicate	AGI	WO 02/100998	12/2002	WIPO			Yes No
	AHI						Yes No
	AII						Yes No
	AJI						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

/F.S./	AKI	Arakawa <i>et al.</i> , "Immunoglobulin gene hyperconversion ongoing in chicken splenic germinal centers", <i>The EMBO Journal</i> 15(10):2540-2546 (1996)
↓	ALI	Arakawa <i>et al.</i> , "Oligoclonal Development of B Cells Bearing Discrete Ig Chains in Chicken Single Germinal Centers", <i>The Journal of Immunology</i> 160:4232-4241 (1998)
↓	AMI	Arakawa <i>et al.</i> , "Mutant IoxP vectors for selectable marker recycle and conditional knock-outs", <i>BMC Biotechnology</i> 1:7 (2001)
↓	ANI	Arakawa <i>et al.</i> , "Requirement of the Activation-Induced Deaminase (AID) Gene for Immunoglobulin Gene Conversion", <i>Science</i> 295:1301-1306 (2002)
Duplicate	AOI	Arakawa <i>et al.</i>, "Immunoglobulin Gene Conversion: Insights From Bursal B Cells and the DT40 Cell Line", <i>Developmental Dynamics</i> 229:458-464 (2004)
/F.S./	API	Bachl <i>et al.</i> , "An immunoglobulin mutator that targets G-C base pairs", <i>Proc. Natl. Acad. Sci. USA</i> , 93:851-855 (1996)

EXAMINER

/Fereydoun Sajjadi/

DATE CONSIDERED

01/24/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>		ATTY. DOCKET NO.	APPLICATION NO.
		21027.002/P30753US00	10/590,211
		APPLICANTS	
		Jean-Marie BUERSTEDDE <i>et al.</i>	
		FILING DATE	GROUP
		August 22, 2006	To Be Assigned 1633
/F.S./	AQ1	Barreto <i>et al.</i> , "C-Terminal Deletion of AID Uncouples Class Switch Recombination from Somatic Hypermutation and Gene Conversion", <i>Molecular Cell</i> 12:501-508 (2003)	
	AR1	Bezzubova <i>et al.</i> , "Reduced X-Ray Resistance and Homologous Recombination Frequencies in a RAD54 ⁻ Mutant of the Chicken DT40 Cell Line", <i>Cell</i> 89:185-193 (1997)	
	AS1	Buerstedde <i>et al.</i> , "Light chain gene conversion continues at high rate in an ALV-induced cell line", <i>The EMBO Journal</i> 9(3):921-927 (1990)	
	AT1	Buerstedde <i>et al.</i> , "Increased Ratio of Targeted to Random Integration after Transfection of Chicken B Cell Lines", <i>Cell</i> 67:179-188 (1991)	
	AU1	Butler, "Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals", <i>Rev. sci. tech. Off. int. Epiz.</i> 17(1):43-70 (1998)	
↓	AV1	Carlson <i>et al.</i> , "Templated insertions in the rearranged chicked IgL V gene segment arise by intrachromosomal gene conversion", <i>Genes & Development</i> 4:536-547 (1990)	
Duplicate	AW1	Diaz <i>et al.</i>, "Evolution of somatic hypermutation and gene conversion in adaptive immunity", <i>Immunological Reviews</i> 162:13-24 (1998)	
/F.S./	AX1	Di Noia <i>et al.</i> , "Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase", <i>Nature</i> 419:43-48 (2002)	
	AY1	Drake <i>et al.</i> , "Rates of Spontaneous Mutation", <i>Genetics</i> 148:1667-1686 (1998)	
	AZ1	Faili <i>et al.</i> , "AID-dependent somatic hypermutation occurs as a DNA single-strand event in the BL2 cell line", <i>Nature Immunology</i> 3(9):815-821 (2002)	
	AA2	Lebecque <i>et al.</i> , "Boundaries of Somatic Mutation in Rearranged Immunoglobulin Genes: 5' Boundary is Near the Promoter, and 3' Boundary is ~1 kb from V(D)J Gene", <i>J. Exp. Med.</i> 172:1717-1727 (1990)	
	AB2	Lundberg <i>et al.</i> , "High-fidelity amplification using a thermostable DNA polymerase isolated from <i>Pyrococcus furiosus</i> ", <i>Gene</i> 108:1-6 (1991)	
↓	AC2	Martin <i>et al.</i> , "Somatic hypermutation of the AID transgene in B and non-B cells", <i>PNAS</i> 99(19):12304-12308 (2002)	

EXAMINER	DATE CONSIDERED
/Fereydoun Sajjadi/	01/24/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 21027.002/P30753US00	APPLICATION NO. 10/590,211
		APPLICANTS Jean-Marie BUERSTEDDE <i>et al.</i>	
		FILING DATE August 22, 2006	GROUP To Be Assigned 1633
/F.S./	AD2	Milstein <i>et al.</i> , "The maturation of the antibody response", <i>Immunoglobulin Genes</i> , 2 nd Edition, pages 57-81 (1995)	
↓	AE2	Muramatsu <i>et al.</i> , "Specific Expression of Activation-induced Cytidine Deaminase (AID), a Novel Member of the RNA-editing Deaminase Family in Germinal Center B Cells", <i>The Journal of Biological Chemistry</i> 274(26):18470-18476 (1999)	
	AF2	Muramatsu <i>et al.</i> , "Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme", <i>Cell</i> 102:553-563 (2000)	
	AG2	Revy <i>et al.</i> , "Activation-Induced Cytidine Deaminase (AID) Deficiency Causes the Autosomal Recessive Form of the Hyper-IgM Syndrome (HIGM2)", <i>Cell</i> 102:565-575 (2000)	
	AH2	Reynaud <i>et al.</i> , "A Hyperconversion Mechanism Generates the Chicken Light Chain Preimmune Repertoire", <i>Cell</i> 48:379-388 (1987)	
	Duplicate	AI2	Sale <i>et al.</i>, "TdT Accessible Breaks Are Scattered over the Immunoglobulin V Domain in a Constitutively Hypermutating B Cell Line", <i>Immunity</i> 9:859-869 (1998)
/F.S./	AJ2	Sale <i>et al.</i> , "Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation", <i>Nature</i> 412:921-926 (2001)	
/F.S./	AK2	Ta <i>et al.</i> , "AID mutant analyses indicate requirement for class-switch-specific cofactors", <i>Nature Immunology</i> 4(9):843-848 (2003)	
Duplicate	AL2	Yéclamos <i>et al.</i>, "Targeting of non-Ig sequences in place of the V segment by somatic hypermutation", <i>Nature</i> 376:225-229 (1995)	
/F.S./	AM2	Yoshikawa <i>et al.</i> , "AID Enzyme-Induced Hypermutation in an Actively Transcribed Gene in Fibroblasts", <i>Science</i> 296:2033-2036 (2002)	

EXAMINER /Fereydoun Sajjadi/	DATE CONSIDERED 01/24/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	